Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is aimed to compare the duration of standard anti fungal therapy in high risk ICU patients with a strategy driven by BetaDGlucan test result
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control Group | No Intervention | Patients undergoing empirical anti fungal therapy. Interruption of anti fungal treatment will be decided on the basis of standard clinically and microbiologically criteria. | |
| 1-3 Beta-D-Glucan Group | Experimental | Patients undergoing anti fungal de-escalation according to 1-3 Beta-D-Glucan results |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| duration of antifungal therapy | Other | Patients in the study group will stop antifungals in presence of a negative result of Beta Glucan Test |
|
| Measure | Description | Time Frame |
|---|---|---|
| Reduction of anti fungal duration in the Beta Glucan group compared with standard empirical approach | First 30 days from enrollment |
| Measure | Description | Time Frame |
|---|---|---|
| Clinical Cure of Invasive Canididiasis | 90 days | |
| Microbiological eradication of Invasive Candidiasis | 90 days | |
| 30-day mortality |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Gennaro De Pascale | Rome | 00168 | Italy |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32891170 | Derived | De Pascale G, Posteraro B, D'Arrigo S, Spinazzola G, Gaspari R, Bello G, Montini LM, Cutuli SL, Grieco DL, Di Gravio V, De Angelis G, Torelli R, De Carolis E, Tumbarello M, Sanguinetti M, Antonelli M. (1,3)-beta-D-Glucan-based empirical antifungal interruption in suspected invasive candidiasis: a randomized trial. Crit Care. 2020 Sep 5;24(1):550. doi: 10.1186/s13054-020-03265-y. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 30 days |
| ICU mortality | Any cause ICU mortality within three months from enrollment | 90 days |
| Hospital mortality | Any cause hospital mortality within three months from enrollment | 90 days |
| Duration of ICU length of stay | 90 days |
| Duration of mechanical ventilation | 90 days |
| Number of invasive Candida Infections and Beta-Glucan accuracy | 90 days |
| Cost evaluation (empirical anti fungal therapy vs. Beta Glucan test) | 30 days |